Homepage4507 • TYO
add
Shionogi
Vorige slotkoers
¥ 2.059,00
Dag-range
¥ 2.062,50 - ¥ 2.109,50
Jaar-range
¥ 1.944,66 - ¥ 2.712,33
Beurswaarde
1,86Â bln. JPY
Gem. volume
2,61Â mln.
Koers/winst
11,59
Dividendrendement
2,71%
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 116,38Â mld. | -4,00% |
Bedrijfskosten | 52,93Â mld. | -3,66% |
Netto inkomsten | 52,50Â mld. | 9,30% |
Netto winstmarge | 45,11 | 13,86% |
Winst per aandeel | — | — |
EBITDA | 53,13Â mld. | -5,14% |
Effectief belastingtarief | 8,28% | — |
Balans
Totale activa
Totale passiva
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 303,40Â mld. | 20,22% |
Totale activa | 1,46Â bln. | 3,34% |
Totale passiva | 145,93Â mld. | -18,09% |
Totaal aandelenvermogen | 1,31 bln. | — |
Uitstaande aandelen | 850,69 mln. | — |
Koers-boekwaardeverhouding | 1,23 | — |
Rendement op activa | 8,22% | — |
Rendement op kapitaal | 9,10% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 52,50Â mld. | 9,30% |
Operationele kasstroom | 45,30Â mld. | 220,14% |
Kasstroom uit beleggingen | -17,63Â mld. | 47,30% |
Kasstroom uit financiering | -1,11Â mld. | 94,50% |
Nettomutatie in liquide middelen | 21,45Â mld. | 158,43% |
Vrije kasstroom | 8,02Â mld. | 135,46% |
Over
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Opgericht
1878
Hoofdvestiging
Website
Werknemers
4.959